91.1 F
San Fernando
Saturday, Oct 1, 2022
-Advertisement-
Array

SetPoint Medical Lands $27 Million Investment

SetPoint Medical announced on Thursday that it has received $27 million from previous investors and five institutional investors, including a new venture capital fund at U.K. pharmaceutical company GlaxoSmithKline. The Valencia firm is developing a novel treatment for rheumatoid arthritis and other autoimmune inflammatory diseases. The system consists of a tiny implanted device that stimulates nerves with electricity and produces an anti-inflammatory effect. Investors in the round included Covidien Ventures of Mansfield, Mass., and Boston Scientific of Natick, Mass. Also, SetPoint was the first investment by GlaxoSmithKline’s strategic venture capital fund for bio-electronic technologies called Action Potential Venture Capital Ltd. “This strategic investment from three global leaders in health care technologies, including Boston Scientific, GlaxoSmithKline and Covidien, marks an important inflection point for SetPoint, supporting a novel approach that holds promise as a better way to treat inflammatory diseases,” said Chief Executive Anthony Arnold in a statement. Since 2009, SetPoint has raised nearly $14 million from investors, including Morgenthaler Ventures, Foundation Medical Partners and Topspin Partners.

Joel Russel
Joel Russel
Joel Russell joined the Los Angeles Business Journal in 2006 as a reporter. He transferred to sister publication San Fernando Valley Business Journal in 2012 as managing editor. Since he assumed the position of editor in 2015, the Business Journal has been recognized four times as the best small-circulation tabloid business publication in the country by the Alliance of Area Business Publishers. Previously, he worked as senior editor at Hispanic Business magazine and editor of Business Mexico.
-Advertisement-

Featured Articles

-Advertisement-
-Advertisement-

Related Articles

-Advertisement-
-Advertisement-